Evidence map›Paper›PMID 32643344›Full record

ArticleCroatian medical journal2020

Challenges in the diagnostics and treatment of ectopic ameloblastic carcinoma: a case report.

Marko Tarle, Danko Müller, Antonia Tarle, Igor Blivajs, Naranđa Aljinović Ratković, Predrag Knežević

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Croatian medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marko TarleMarko Tarle, Department of Oral and Maxillofacial Surgery, University Hospital Dubrava, Gojko Šušak Avenue 6, 10000 Zagreb, Croatia, tarlemarko1@gmail.com.
Danko Müller
Antonia Tarle
Igor Blivajs
Naranđa Aljinović Ratković
Predrag Knežević
University of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ameloblastic carcinoma (AC) is a rare and aggressive malignant epithelial odontogenic tumor, most commonly located in the mandible or maxilla. An extremely rare extragnathic localization of AC with no connection to the jaws, ectopic ameloblastic carcinoma (EAC), has so far been described only three times. This report presents a 64-year-old male with skull base ameloblastic carcinoma and offers a review of diagnostic and treatment challenges related to EAC. Because of its rarity and histological similarity to other tumors, EAC is often misdiagnosed. This is why we established a pathohistological and immunohistochemical profile of EAC that differentiates it from histologically similar tumors. The most frequently used EAC treatment is radical surgical resection, but the majority of reviewed reports described local recurrence. Taking into consideration new scientific discoveries on the molecular pathogenesis of ameloblastoma, we are the first to have performed BRAF mutation analysis in an EAC patient. BRAF inhibitors offer promising results in the treatment of BRAF-positive ameloblastomas and should continue to be researched in AC and EAC patients. Finally, EAC should be considered in differential diagnosis of head and neck tumors outside the jaws.

Indexed as

Paranasal Sinus NeoplasmsAmeloblastomaChoristomaDNA Mutational AnalysisFatal OutcomeHumansMagnetic Resonance ImagingMaleMiddle AgedNasal CavityNeoplasm Recurrence, LocalOdontogenic TumorsPolymerase Chain ReactionProto-Oncogene Proteins B-rafTomography, X-Ray ComputedBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID32643344
PMCPMC7358694
OpenAlexW3040699215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.